Lazard Asset Management
AKRO

Lazard Asset Management’s Akero Therapeutics AKRO Stock Holding History

Lazard Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,349
Closed -$296K – 2248
2023
Q2 		$296K Buy
+6,349
New +$291K ﹤0.01% 1239

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Lazard Asset Management's AKRO Position: Q3 2023 in Review

Lazard Asset Management sold out of Akero Therapeutics (AKRO) in Q3 2023, closing a stake of 6,349 shares — an estimated $296K sold.

Lazard Asset Management first reported a position in AKRO in Q2 2023 and held it in 1 quarter. The position peaked at $296K in Q2 2023. 181 funds tracked by Wall St. Rank hold AKRO as of Q3 2023.

  • Lazard Asset Management reported no remaining Akero Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Lazard Asset Management sold 6,349 Akero Therapeutics shares in Q3 2023, an estimated $296K.
  • Lazard Asset Management first reported a position in Akero Therapeutics in Q2 2023 and held it in 1 quarter.
  • Lazard Asset Management's Akero Therapeutics position peaked at $296K in Q2 2023.
  • 181 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2023.

Based on Lazard Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.